Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

IARTยทNASDAQ

$16.10

+2.7%
HealthcareMedical - Devices

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

At a Glance

Live Snapshot
Market Cap$1.25B
EPS-6.7300
P/E Ratio-2.39
Earnings Date07/30/2026

SEC Filings

IART - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 08, 2026
May 07, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
May 05, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 05, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
April 30, 2026
2026
8-K

8-K 2026

N/A

April 15, 2026
April 10, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 06, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2025

N/A

December 12, 2025
December 11, 2025
2025
10-Q

10-Q 2025 Q3

Q3

October 30, 2025
September 30, 2025
2025
Showing 1 to 10 of 575 filings

Understanding SEC Filings

Essential regulatory documents for investors

SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.

10-K

Annual Report

Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.

Filed annually
10-Q

Quarterly Report

Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.

Filed 3 times per year
8-K

Current Report

Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.

Filed as events occur
DEF 14A

Proxy Statement

Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.

Filed before shareholder meetings
S-1

Registration Statement

Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.

Filed for new offerings
20-F

Foreign Annual Report

Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.

Foreign companies only

Why SEC Filings Matter

  • Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
  • Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
  • Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
  • Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
  • Historical Context: Years of filings provide trend analysis and context for current performance